公开(公告)号：US20160000683A1

公开(公告)日：2016-01-07

申请号：US14771372

申请日：2014-02-27

Applicant: AMOREPACIFIC CORPORATION

Inventor： Hyun Jung SHIN ,  Jin Kyu CHOI ,  Byung Gyu KIM ,  Dae Bang SEO ,  Sang Jun LEE

IPC: A61K8/65 ,  A61Q19/00 ,  A23L1/305 ,  A61K8/73

CPC classification number: A61K8/65 ,  A23L33/18 ,  A23V2002/00 ,  A61K8/735 ,  A61K9/0095 ,  A61K9/2059 ,  A61K9/4875 ,  A61K31/728 ,  A61K36/258 ,  A61K38/005 ,  A61K38/06 ,  A61K38/39 ,  A61K2800/91 ,  A61Q19/00 ,  A61Q19/08 ,  A61K2300/00

Abstract: The present invention relates to a composition for maintaining efficacy of a filler for a long period of time by containing collagen as an active ingredient. The composition according to the present invention is useful since the composition can promote the synthesis of hyaluronic acid and inhibit activity of hyaluronidase, thereby maintaining the efficacy of a hyaluronic acid filler for a longer period of time. Therefore, even with less number of times of filler injection, the efficacy of the filler can be maintained and skin irritation can be also reduced.

Abstract translation: 本发明涉及通过含有胶原作为有效成分来长期维持填充剂的功效的组合物。 根据本发明的组合物是有用的，因为组合物可以促进透明质酸的合成并抑制透明质酸酶的活性，从而保持透明质酸填充剂的更长时间的功效。 因此，即使填充剂注射次数较少，也可以保持填充剂的功效，并且还可以减少皮肤刺激。

公开(公告)号：US20170136146A1

公开(公告)日：2017-05-18

申请号：US15127399

申请日：2015-03-10

Applicant: AMOREPACIFIC CORPORATION

Inventor： Hyun Jung SHIN ,  Jin Kyu CHOI ,  Byung Gyu KIM ,  Dae Bang SEO

IPC: A61L27/24 ,  A61L27/50 ,  A61L27/20

CPC classification number: A61L27/24 ,  A61L27/20 ,  A61L27/505 ,  A61L27/52 ,  A61L2400/06 ,  C08L5/08

Abstract: The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin.

公开(公告)号：US20140011881A1

公开(公告)日：2014-01-09

申请号：US14022789

申请日：2013-09-10

Applicant: Amorepacific Corporation

Inventor： Song Seok SHIN ,  Jin Kwan KIM ,  Sun-Young KIM ,  Ki-Wha LEE ,  Byoung young WOO ,  Joo-Hyun MOH ,  Yeon Su JEONG ,  Kyung Min LIM ,  Jin Kyu CHOI ,  Hyun-Ju KOH ,  Young-Ho PARK

IPC: C07C311/08

CPC classification number: C07C311/08 ,  C07C2601/14 ,  C07D295/145

Abstract: This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same.The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

Abstract translation: 本公开涉及新化合物，其异构体或其药学上可接受的盐作为香草素受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂; 和含有该组合物的药物组合物。 本公开提供了用于预防或治疗诸如疼痛，偏头痛，关节痛，神经痛，神经病，神经损伤，皮肤病，尿膀胱过敏症，肠易激综合征，粪便紧急性，呼吸障碍，皮肤刺激， 眼或粘膜，胃十二指肠溃疡，炎性疾病，耳病，心脏病等。